Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Angelica, Carletto"'
Autor:
Pierluigi Russo, Matteo Zanuzzi, Angelica Carletto, Annalisa Sammarco, Federica Romano, Andrea Manca
Publikováno v:
PharmacoEconomics. 41:107-117
The main objective of this study was to explore the extent to which the incremental cost-effectiveness ratio (ICER), alongside other factors, predicts the final outcome of medicine price negotiation in Italy. The second objective was to depict the me
Publikováno v:
Health Policy. 125:1140-1145
Pricing of pharmaceuticals is an all-time challenge for healthcare systems. Often public payers agree with companies on confidential managed-entry agreements (MEAs) that, e.g. foresee discounts under specific circumstances. The EURIPID Executive Comm
Publikováno v:
International Journal of Technology Assessment in Health Care. 36:560-568
ObjectivesThe purpose of this study was to evaluate the current state of health economic evaluations (HEEs) submitted by pharmaceutical companies to the Italian Medicines Agency (AIFA) as part of their pricing and reimbursement (P&R) dossiers, and to
Autor:
Matteo Zanuzzi, Pierluigi Russo, Maria Elisabetta Fratto, Angelica Carletto, Andrea Marcellusi, Tommaso Staniscia, Ferdinando Romano, Giampiero Favato
Publikováno v:
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 24(9)
Objective The main objective of this study was to evaluate the potential role of efficacy data and other information available at the time of price and reimbursement (P&R) decision-making process within the definition of oncology treatment costs in I
Publikováno v:
Eurasian Business Review. 9:89-101
The aim of this paper is to provide an empirical framework based on a discrete-time Markov chain to assess the costs and benefits of Performance Based Agreements (PBAs) for the reimbursement of pharmaceuticals. We provide an empirical testing using a
Publikováno v:
PharmacoEconomics Italian Research Articles. 15:65-74
The aim of this study was to assess whether S-1 might represent a valuable therapeutic option for patients with advanced gastric cancer in comparison to other available therapies (5-FU, capecitabine), considering both costs and outcomes associated wi
Autor:
Francesco Saverio Mennini, Marco Marchetti, Angelica Carletto, Valentina Iacopino, Americo Cicchetti
Publikováno v:
Giornale Italiano di Health Technology Assessment. 4:69-77
The aim of this paper is to identify the stakeholders involved in the Health Technology Assessment (HTA) process with particular attention to their role and potential contribution from patients and citizens. Moreover, a focus on elements to be shared